Rights Issue Offer Document

TRUSCREEN GROUP LIMITED | RIGHTS ISSUE OFFER DOCUMENT l 1
TruScreen Group Limited
Rights Issue Offer Document
1 for 5 renounceable rights
offer of ordinary shares
Dated 28 February 2023
A world
without
cervical
cancer.
This Offer Document is an important document. You should read the whole document before
deciding what action to take with your Rights. If you have any doubts as to what you should
do, please consult your broker, financial, investment or other professional advisor. This Offer
Document may not be distributed outside New Zealand or Australia.
©

TRUSCREEN GROUP LIMITED | RIGHTS ISSUE OFFER DOCUMENT l 1
Contents
Important Information2
Letter from the Chair4
Key Terms of the Offer5
Important Dates7
Actions to be taken by Eligible Shareholders 8
Business Overview 11
Terms of the Offer 14
Glossary19
Directory21

TRUSCREEN GROUP LIMITED | RIGHTS ISSUE OFFER DOCUMENT l 2
Important Information
Additional information available under TruScreen’s
disclosure obligations
TruScreen is subject to continuous disclosure
obligations under the NZX Main Board Listing Rules.
Further information relating to the Offer can also be
found in TruScreen’s recent market announcements
and its most recent unaudited financial statements
for the six-month period ended 30 September 2022,
which can be accessed online at www.nzx.com under
the ticker code “TRU”.
TruScreen may, during the Offer, make additional
releases to NZX. To the maximum extent permitted
by law, no release by TruScreen to NZX will permit
an Applicant to withdraw any previously submitted
Application without TruScreen’s prior consent.
We encourage you to read this document and to
seek investment advice from a suitably qualified
professional adviser before you consider investing.
Offering restrictions
This Offer Document is intended for use only in
connection with the Offer to Eligible Shareholders. To
be an Eligible Shareholder you must be:
• A Shareholder with a registered address in New
Zealand; or
• A Shareholder with a registered address in
Australia.
This Offer Document does not constitute an offer or
invitation in any country in which, or to any person to
whom, it would not be lawful to make such an offer or
invitation.
This Offer Document may not be sent or given to
any person outside New Zealand or Australia. The
distribution of this Offer Document (including an
electronic copy) outside New Zealand or Australia may
be restricted by law. In particular, this Offer Document
may not be distributed to any person, and the New
Shares may not be offered or sold, in any country
outside New Zealand or Australia except as detailed
in this Offer Document, or as TruScreen may otherwise
determine in compliance with applicable laws.
Neither this Offer Document nor the Application Form
may be released or distributed in the United States.
General Information
This Offer Document has been prepared by TruScreen
Group Limited (TruScreen) in connection with a 1 for 5
renounceable rights offer of New Shares, followed by
an Oversubscription Bookbuild Facility (Offer).
The Offer is made to Eligible Shareholders in New
Zealand pursuant to the exclusion in clause 19 of
schedule 1 of the Financial Markets Conduct Act 2013
(FMCA).
This Offer Document is not a product disclosure
statement for the purposes of the FMCA, and does not
contain all of the information that an investor would
find in a product disclosure statement or which may
be required to make an informed decision about the
Offer or TruScreen.
The Offer is made to Eligible Shareholders in Australia
pursuant to the provisions of the Corporations
Act 2001 (Cth) (Corporations Act) (as modified by
Australian Securities and Investments Commission
(ASIC) Corporations (Non-Traditional Rights Issues)
Instrument 2016/84 (ASIC Instrument 2016/84) and
ASIC Instrument 23-0122. The Rights will not be quoted
on the NZX Main Board or the Australian Securities
Exchange (ASX).
This Offer Document is not a prospectus, product
disclosure statement or any other formal disclosure
document for the purposes of Australian law or the
Corporations Act and is not required to, and does not,
contain all the information which would be required
in a disclosure document under Australian law or
the Corporations Act. It may contain references to
dollar amounts which are not Australian dollars, may
contain financial information which is not prepared
in accordance with Australian law or practices, may
not address risks associated with investment in foreign
currency denominated investments and does not
address Australian tax issues. TruScreen is a company
which is incorporated in New Zealand and the
relationship between it and investors will be largely
governed by New Zealand law.
This Offer Document has not been, and will not be,
lodged or registered with ASIC and TruScreen is not
subject to the continuous disclosure requirements
under the Corporations Act or the ASX Listing
Rules. TruScreen is only required to comply with the
continuous disclosure rules of the NZX Listing Rules.
Prospective investors should not construe anything in
this Offer Document as legal, business or tax advice
nor as financial product advice for the purposes of
Chapter 7 of the Corporations Act.

TRUSCREEN GROUP LIMITED | RIGHTS ISSUE OFFER DOCUMENT l 3
Forward looking statements
This document contains certain statements that relate
to the future. Such forward looking statements are not
a guarantee of future performance and involve known
and unknown risks, uncertainties, assumptions and
other factors, many of which are beyond the control
of TruScreen and which may cause the actual results,
performance or achievements of TruScreen to differ
materially from those expressed or implied by such
statements.
Under no circumstances should you regard the inclusion
of forward looking statements in this document as a
guarantee of future performance.
The statements, although made in good faith,
involve known and unknown risks, uncertainties and
assumptions, many of which are beyond the control
of TruScreen.
Withdrawal and date changes
Subject to compliance with all applicable laws,
TruScreen reserves the right at its absolute discretion to:
• withdraw all or any part of the Offer and the issue
of New Shares; and/or
• alter any dates set out in this Offer Document.
Enquiries
Enquiries about the Offer can be directed to an NZX
Firm, an authorised financial advisor, or your solicitor,
accountant or other professional adviser. If you have
any questions about the number of New Shares shown
on your Entitlement and Acceptance Form, or how
to complete the Entitlement and Acceptance Form
or online application, please contact the Registrar,
whose contact details are set out in the Directory.
Times, currency and laws
All references in this Offer Document to times and dates
are to times and dates in New Zealand. All references
in this Offer Document to currency are to New Zealand
dollars, and all references to applicable statutes and
regulations are references to New Zealand statutes
and regulations.
Defined terms
Capitalised terms used in this Offer Document have
the meaning given to them in the Glossary in the
relevant section of this Offer Document.
No guarantee
No guarantee is provided by any person in relation
to the New Shares to be issued under the Offer.
Likewise, no warranty is provided with regard to the
future performance of TruScreen or any return on any
investment made pursuant to this Offer Document.
Eligible Shareholders should be aware that there are
risks associated with investing in the New Shares. The
principal risk is that Eligible Shareholders may not be
able to recoup the Issue Price and/or may not receive
any dividends, entitlements or other distributions in
respect of the New Shares. In addition, the market for
the New Shares may not be liquid. If liquidity is low,
Eligible Shareholders may be unable to sell their New
Shares at an acceptable price or at all.
Disclaimer
CM Partners Limited has not been responsible for the
preparation of, and to the maximum extent permitted
by law accepts no liability in connection with, this
Offer Document.
Privacy
Any personal information provided in your Application
will be held by TruScreen and the Registrar at the
addresses set out in the Directory. This information
will be used for the purposes of administering your
investment in TruScreen and will be disclosed to
third parties only with your consent or if required by
law. Under the Privacy Act 2020 (New Zealand) you
have the right to access and correct any personal
information held about you.
Dividend policy
The payment of dividends is at the discretion of the
Board. The Board has no present intention to make
a distribution for the foreseeable future. This policy
may change from time to time at the discretion of the
Board in the future.
Decision to participate in the Offer
The information in this Offer Document does not
constitute a recommendation to acquire New Shares
nor does it amount to financial product advice. This
Offer Document has been prepared without taking
into account the particular needs or circumstances
of any Applicant or investor, including their investment
objectives, financial or tax position. Before deciding
whether to invest in the New Shares, you must make
your own assessment of the risks associated with
an investment in TruScreen, and consider whether
such an investment in TruScreen is suitable for you
having regard to publicly available information
about TruScreen, your personal circumstances and
following consultation with a financial adviser or other
professional adviser.
IMPORTANT INFORMATION

TRUSCREEN GROUP LIMITED | RIGHTS ISSUE OFFER DOCUMENT l 4
Letter from the Chair
Eligible Shareholders are entitled to take up
one New Share for every five Existing Shares
held. Eligible Shareholders and other parties
may also apply for additional New Shares
pursuant to the Oversubscription Bookbuild
Facility. Further information about the
Oversubscription Bookbuild Facility is provided
in this Offer Document.
Eligible Shareholders have until 5:00pm (NZDT)
on 15 March 2023 to apply for New Shares
under the Offer.
Shareholders who choose not to take up their
Rights entitlements will have their percentage
shareholding diluted.
This document sets out important information
about TruScreen and the Offer. Before making
your investment decision, I encourage you
to read these documents in full and also to
consider the information disclosed by TruScreen
to NZX and other information available at
www.nzx.com under the ticker code “TRU”.
If you are in doubt as to what you should do,
you should consult your financial or professional
adviser.
I advise that directors who hold shares
in TruScreen intend to take up their full
entitlements of Rights.
Yours sincerely
Tony Ho
Chairman | TruScreen Group Limited
TruScreen has made commendable progress
through a difficult COVID period, during which it
has enhanced the product, service capability,
and quality processes and expanded its
market reach into new countries.
Notable achievements include establishing a
manufacturing facility in China with TruScreen
now registered as a domestic medical device
with a ‘Made in China’ mark, gaining wider
product acceptance, presenting independent
and large study results at two eminent
congresses in the US and India, and establishing
support from Global Key Opinion Leaders
through the formation of an International
Experts Group and conducting the first ever
Medically Led Symposium on TruScreen.
With the pandemic behind us, TruScreen is
now well positioned to increase product sales
through channels developed in existing and
new markets, in China, Vietnam, Africa, Eastern
Europe, Central Asia, South America and Middle
East Gulf States. Key to our success going
forward includes providing outstanding training
and service support to our distributors and
ongoing manufacturing process improvements
to reduce our cost of goods sold.
TruScreen has an outstanding product,
motivated team and distributors, and demand
for its product supported by member nations
of the World Health Organisation (WHO)
global strategy to eliminate cervical cancer
by the end of the century. Funds raised will be
used to support working capital required as
the business grows, support our distributors
with marketing collateral and training to assist
them in growing their markets, and funding
initiatives to optimise business performance in
our drive to profitability.
Dear fellow shareholder,
On behalf of the directors of TruScreen Group Limited we are pleased to offer eligible
shareholders the opportunity to participate in a 1 for 5 renounceable rights issue at
an issue price of NZ$0.03 per share (A$0.029), to raise up to NZ$2,177,197 (A$2,104,624).
The Rights will not be quoted on the NZX. Eligible shareholders will also be able to bid
for additional shares through an Oversubscription Bookbuild Facility.

TRUSCREEN GROUP LIMITED | RIGHTS ISSUE OFFER DOCUMENT l 5
Key Terms of the Offer
IssuerTruScreen Group Limited.
The OfferA renounceable rights offer of one New Share for every Five Existing
Shares held on the Record Date (being 5.00pm (NZDT), 27 February
2023), with fractional entitlements being rounded down to the
nearest share.
New Shares which pertain to Rights not taken up by Eligible
Shareholders, or which are attributable to Ineligible Shareholders,
will be offered through the Oversubscription Bookbuild Facility run
by the Issuer and its advisors.
Any premium achieved above the Issue Price for the New Shares
pursuant to the Oversubscription Bookbuild Facility will be paid,
after the deduction of any brokerage costs incurred, on a pro-rata
basis to those Shareholders who did not take up their Rights or who
are Ineligible Shareholders.
Eligible ShareholdersShareholders with registered addresses in New Zealand or Australia
on the Record Date.
Issue PriceNZ$0.03 or (A$0.029, being the A$ price) per New Share.
Offer SizeUp to NZ$2,177,197 (or A$2,104,624). In the event that TruScreen
receives subscriptions for more than NZ$2,177,197 under the Offer
and the Oversubscription Bookbuild Facility, it reserves the right to
issue additional Shares under the 15% placement Listing Rule or in
any other manner it may lawfully do so.
Shares currently on issue362,866,253 Shares quoted on the NZX Main Board.
Maximum number of New
Shares being offered
72,573,250 New Shares (subject to rounding, and to TruScreen’s right
to issue further shares under the Listing Rules).
RightsEligible Shareholders have an entitlement to subscribe for one New
Share for every five Existing Shares held on the Record Date (5.00pm
(NZDT), 27 February 2023) at the Issue Price. Eligible Shareholders
may take up some, or all, or none of their Rights.
Your Rights may have value. If you do nothing, your Rights will lapse
and you will not be able to subscribe for any New Shares and may not
realise any value for your Rights in the Oversubscription Bookbuild
Facility. If you do not take up all of your Rights, your shareholding
percentage in TruScreen will also be diluted.
No Rights tradingThe Rights will not be quoted on the NZX Main Board or the ASX,
and accordingly there will be no established market for Rights. If
you wish to sell your Rights privately to a buyer you identify, you
should contact the Registrar, Link Market Services (see Directory), to
request a Security Renunciation Form.
TRUSCREEN GROUP LIMITED | RIGHTS ISSUE OFFER DOCUMENT l 5

TRUSCREEN GROUP LIMITED | RIGHTS ISSUE OFFER DOCUMENT l 6
Oversubscription
Bookbuild Facility
Eligible Shareholders who take up all of their Rights are entitled to
apply for additional New Shares pursuant to the Oversubscription
Bookbuild Facility. This process may also involve institutional and
other investors.
Any additional New Shares applied for under the Oversubscription
Bookbuild Facility will be issued at the Oversubscription Price. The
Oversubscription Price may ultimately be the same as, or greater
than, the Issue Price. In no event will the Oversubscription Price be
less than the Issue Price.
Eligible Shareholders who take up their Rights in full and other parties
may also apply for New Shares under the Oversubscription Bookbuild
Facility through those NZX Firms and other market participants that
have been invited to participate in the Oversubscription Bookbuild
Facility by TruScreen.
The Oversubscription Bookbuild will occur on 15 and 16 March 2023.
When to applyApplication (including postal applications) must be received by
5:00pm (NZDT) on the Closing Date (15 March 2023, unless extended).
How to applyAn application by an Eligible Shareholder must be made either:
• online at https://Truscreen.rightsoffer.co.nz. To complete an
online application, you will be required to enter your CSN/Holder
number; or
• by returning the Entitlement and Acceptance Form and following
the payment instructions on that form.
If, before the Closing Date, TruScreen receives both an Entitlement
and Acceptance Form and a renunciation in respect of the same
Rights, TruScreen will give priority to the renunciation, and the
Entitlement and Acceptance Form will not be accepted in respect
of those Rights.
No UnderwritingThe Offer is not underwritten.
DilutionWhilst an Eligible Shareholder is not obliged to participate in the
Offer, it is important to note that if an Eligible Shareholder chooses
not to participate in the Offer, then their shareholding will be diluted
down accordingly.
KEY TERMS OF THE OFFER
TRUSCREEN GROUP LIMITED | RIGHTS ISSUE OFFER DOCUMENT l 6

TRUSCREEN GROUP LIMITED | RIGHTS ISSUE OFFER DOCUMENT l 7
Important Dates
EventDate
Announcement of the Offer17 February 2023
Record Date5.00pm (NZDT) / 3.00pm (AEDT)
on 27 February 2023
Opening Date for the Offer28 February 2023
Dispatch of Offer Documents and Entitlement and
Acceptance Forms
28 February 2023
Closing Date for the Offer5:00pm (NZDT) / 3.00pm (AEDT)
on 15 March 2023
Closing Date for the Oversubscription Bookbuild Facility 16 March 2023
Announcement of results of the Offer and the
Oversubscription Bookbuild Facility
17 March 2023
Allotment of New Shares, despatch of holder statements
and commencement of trading of New Shares
22 March 2023
Payment of any premium achieved from Oversubscription
Bookbuild Facility to holders of unexercised Rights
by 24 March 2023
Payment of any refund from scaling of Offer and/or
Oversubscription Bookbuild Facility
by 24 March 2023
The dates above are subject to change and are indicative only. TruScreen reserves the right to
amend this timetable (including by extending the Closing Date) subject to applicable laws and the
Listing Rules. TruScreen reserves the right to withdraw the Offer at any time at its absolute discretion.
TRUSCREEN GROUP LIMITED | RIGHTS ISSUE OFFER DOCUMENT l 7

TRUSCREEN GROUP LIMITED | RIGHTS ISSUE OFFER DOCUMENT l 8
Actions to be taken by
eligible Shareholders
Taking up your Entitlement
Eligible Shareholders who wish to take up all or
some of their Rights should:
• complete their Entitlement and Acceptance
Form and deliver it to the Share Registrar,
along with payment of the Issue Price in full
by direct debit, by no later than the Closing
Date in accordance with the instructions
set out in the Entitlement and Acceptance
Form; or
• apply online in accordance with the
instructions for online applications on the
Entitlement and Acceptance Form.
There is no minimum number of New Shares
that you must subscribe for under the Offer.
Applicants will not be treated as having offered
to purchase a greater number of New Shares
than the number for which payment is made.
Applying to subscribe for more new shares
under the Oversubscription Bookbuild Facility
Eligible Shareholders who wish to apply for
additional New Shares in excess of their
Entitlement may apply for an additional number
of New Shares in excess of the Rights they hold by
participating in the Oversubscription Bookbuild
Facility, via either of the following processes:
• Apply for additional New Shares through
the Acceptance Form or online application
process on the website for the offer https://
Truscreen.rightsoffer.co.nz, provided that
the Eligible Shareholder has taken up all
of their Rights in full, and apply for the
dollar amount of New Shares under the
Oversubscription Bookbuild Facility where
provided on the Application Form. If you
do not accept your Rights in full, your
Application for any New Shares under
the Oversubscription Bookbuild will be
disregarded; or
Available Actions
If you are an Eligible Shareholder, accompanying
this Offer Document is an Entitlement and
Acceptance Form showing the number of
Rights to subscribe for New Shares that you
are entitled to under the Offer. You may take
one or more of the following actions:
• take up all or some of your Rights; or
• take up all of your Rights and apply
for additional New Shares in the
Oversubscription Bookbuild Facility; or
• sell all or some of your Rights privately; or
• take up some of your Rights, and sell all or
some of the remaining balance privately; or
• do nothing with all or some of your Rights.
If you do nothing with your Rights before the
Closing Date, they will lapse and you will not
be able to subscribe for any New Shares under
the Offer and may not realise any value for
your Rights in the Oversubscription Bookbuild
Facility.
The Offer is an offer to Eligible Shareholders only.
If you take up all of your Rights your percentage
shareholding in TruScreen will not reduce
(subject to TruScreen not issuing additional
New Shares in addition to those being offered
under this Offer), but if you do not take up all
your Rights, your percentage shareholding will
reduce following the completion of the Offer.
For example, if you hold 5,000 Shares on the
Record Date, you will have 1,000 Rights. If you
decide not to take up any of your Rights, and all
other shareholders do take up their Rights, your
percentage interest in TruScreen will be diluted.

TRUSCREEN GROUP LIMITED | RIGHTS ISSUE OFFER DOCUMENT l 9
ACTIONS TO BE TAKEN BY ELIGIBLE SHAREHOLDERS
Please note that if the buyer of your Rights
is an Ineligible Shareholder or a person that
would be an Ineligible Shareholder were they
a registered holder of Shares, that buyer will
not be able to take up the Rights they have
purchased.
Renunciations must be lodged with the Share
Registrar, Link Market Services Limited, not
later than the Closing Date (5.00pm (NZDT) on
15 March 2023). The Share Registrar’s details for
the return of your Entitlement and Acceptance
Form are set out in the Directory.
Accepting some of your Entitlement and selling
the balance
There is no minimum number of New Shares
that you must subscribe for under the Offer.
You may take up as many or as few of your
Rights as you wish. If you wish to take up some
of your Rights and sell the balance, you should:
• Make arrangements privately to sell the
number of Rights you wish to sell; and
• indicate the number of New Shares you
wish to apply for in the Entitlement and
Acceptance Form and send your completed
Entitlement and Acceptance Form to the
Registrar, or submit your Application online,
together with payment for the number of
New Shares applied for.
If TruScreen receives, on or before the Closing
Date (5.00pm (NZDT) on 15 March 2023) both
an acceptance and a renunciation by an
Eligible Shareholder in respect of the same
Rights, effect will be given to the renunciation
in priority to the acceptance.
• You may participate in the Oversubscription
Bookbuild Facility through those NZX Firms
that have been invited to participate in
the Oversubscription Bookbuild Facility
by TruScreen. Those NZX Firms will provide
you with instructions as to how you
may participate in the Oversubscription
Bookbuild Facility.
The issue price for the New Shares to be issued
pursuant to the Oversubscription Bookbuild
Facility will be determined by TruScreen and its
advisors by reference to the Oversubscription
Bookbuild Facility having regard to the bids for
New Shares received (and their corresponding
number of New Shares bid for at those levels)
from those NZX Firms and institutions invited
to bid into the Oversubscription Bookbuild
Facility. In no event will the issue price for
the New Shares under the Oversubscription
Bookbuild Facility be less than the Issue Price,
however it may be equal to, or greater than
the Issue Price.
The number of New Shares that you may
receive under the Oversubscription Bookbuild
Facility will be determined by TruScreen and
will be subject to the allocation made to you
and the final issue price for New Shares struck
under the Oversubscription Bookbuild Facility.
TruScreen may scale the Oversubscription
Bookbuild Facility applications in such manner
as the directors of TruScreen consider equitable
and in the interests of TruScreen. Applications
received from those shareholders of TruScreen
who held Shares in TruScreen on the Record
Date will be given preference over those third
parties who apply for New Shares pursuant to
the Oversubscription Bookbuild Facility and
who did not hold Shares in TruScreen as at the
Record Date. The directors’ decision on scaling
will be final.
Selling your Entitlement
The Rights will not be quoted on the NZX Main
Board or the ASX, and accordingly there will be
no established market for Rights. If you wish to
sell your Rights privately to a buyer you identify,
you should contact Link Market Services (see
Directory) to request a Security Renunciation
Form.

TRUSCREEN GROUP LIMITED | RIGHTS ISSUE OFFER DOCUMENT l 10
ACTIONS TO BE TAKEN BY ELIGIBLE SHAREHOLDERS
Your application is irrevocable and cannot be
withdrawn. TruScreen has the sole discretion to
accept or reject your application for New Shares.
Payment
If you are an NZX Shareholder, you must:
• elect to apply using New Zealand dollars
at the NZ$ Offer Price; and
• pay for your New Shares by way of direct
debit.
If you are an ASX Shareholder, you must:
• elect to apply using Australian dollars at
the A$ price; and
• pay for your New Shares by way of BPAY®.
If you are a Custodian (or you hold your Shares
through a Custodian), please see paragraph
14.1 of Part 4: Terms of the Offer.
Cheques will not be accepted. Payment must
be made for both your Rights and the dollar
amount of Additional New Shares that you
are applying for under the Oversubscription
Bookbuild Facility (if any).
If any scaling is applied to the application for
Additional New Shares in the Oversubscription
Bookbuild Facility, a refund of any extra
application monies will be processed within
five Business Days of the Allotment Date.
Refunds will not be paid for any difference
arising solely due to rounding or where the
aggregate amount of the refund payable to
you is less than NZ$5.00.
More detail on payment options is included in
the Entitlement and Acceptance Form.
Enquiries
If you have any queries about the number
of Rights shown on the Entitlement and
Acceptance Form which accompanies this
Offer Document, or how to complete the
Entitlement and Acceptance Form, please
contact the Share Registrar (refer to the
Directory for contact details).
You may elect to do nothing
Your Rights may have value. If you do nothing,
your rights will lapse and you will not be able
to subscribe for any New Shares and may
not realise any value for your Rights in the
Oversubscription Bookbuild.
In that event that a premium above the Issue
Price for the New Shares to be issued pursuant
to the Oversubscription Bookbuild Facility is
achieved, that premium will be paid, after the
deduction of any brokerage costs incurred, on
a pro-rata basis to those Shareholders who did
not take up their Rights or who are Ineligible
Shareholders.
How to apply for New Shares
An application by an Eligible Shareholder must
be made either:
• online at https://truscreen.rightsoffer.co.nz.
To complete an online application, you
will be required to enter your CSN/Holder
number; or
• by returning the Entitlement and
Acceptance Form to the Registrar, and
following the payment instructions on that
form.
If you elect to participate in the Oversubscription
Bookbuild Facility, you must also make payment
for both your Rights entitlement, together with
the amount that you wish to oversubscribe for.
In the event that all or part of your application
for New Shares in the Oversubscription
Bookbuild Facility is not successful, then
TruScreen will refund any extra application
monies to you within five Business Days of the
Allotment Date.
By completing and returning an Entitlement
and Acceptance Form (or completing the
online application) and applying for New
Shares, you agree to accept the New Shares:
• subject to the terms set out in the
constitution of TruScreen; and
• on the terms set out in this Offer Document
and the Entitlement and Acceptance Form.

TRUSCREEN GROUP LIMITED | RIGHTS ISSUE OFFER DOCUMENT l 11
Business Overview
Our Strategy
TruScreen is seeking to further develop and
expand its sales and distribution channels to
increase sales of its device and its consumable
Single Use Sensors (SUS) in its targeted and
new markets. Several initiatives to improve
financial performance are in place. TruScreen
has the following short-term strategy:
• Rapidly expand sales in China, leveraging
off the China manufacture facility which
allows TruScreen to access the China
markets with its domestic “Made In China”
product;
• Support and develop other key Low- and
Middle-Income Country (LMICs) markets of
Vietnam, Zimbabwe (as base to expand
in Africa), Poland (as base to expand in
Central and Eastern Europe), Saudi Arabia
(as base to expand in Middle Easter and
Gulf States) and Central Asia using the
existing distributor in Russia/Kazakhstan;
and
• Working closely with its exclusive SUS
manufacturer to reduce SUS and logistic
costs.
Longer term, TruScreen will:
• Expand the existing market presence to
grow into new, large population markets in
Africa, Gulf States, and others;
• Conduct the Health Technology
Assessments to enable regulators to adopt
TruScreen as a preferred cervical screening
method; and
• Add new products and services to the
portfolio.
Who is TruScreen?
TruScreen Group Limited (NZX/ASX: TRU) is a
New Zealand-based medical device company
that has developed and commercialises an
AI-enabled device for detecting abnormalities
in the cervical tissue in real-time via
measurements of the low level optical and
electrical stimuli responses. TruScreen is listed
on the NZX Main Board, and is also listed on
the ASX as an ASX Foreign Exempt Listing.
TruScreen’s cervical screening technology
enables cervical screening without invasive
tissue sampling and processing of tissues,
thereby avoiding issues with failed samples,
missed follow-up, discomfort, and the need
for costly, specialised personnel and expensive
laboratory infrastructure.
The TruScreen device, TruScreen ® Ultra, is
registered as a primary screening tool for
cervical cancer screening. The device is EC
certified (CE Mark), ISO 13485 compliant and
is registered for clinical use with the TGA
(Australia), MHRA (UK), NMPA (China), SFDA
(Saudi Arabia), Roszdravnadzor (Russia), and
COFEPRIS (Mexico). It has Ministry of Health
approval for use in Vietnam, Zimbabwe, Israel,
Ukraine, and the Philippines, among others
and has active distributors in 23 countries. It is
also National Medical Products Administration
(NMPA) approved for sale in China. In 2021,
TruScreen established a manufacturing facility
in China for devices marketed and sold in China
as a domestic, Made In China medical device.
To date, over 170000
1
examinations had been
performed with TruScreen device and over 200
devices have been installed and used in China,
Vietnam, Mexico, Zimbabwe, Russia, and Saudi
Arabia.
TruScreen’s vision is
“A world without cervical cancer ”
To learn more, please visit: www.truscreen.com
©
1 Based on SUS sales

TRUSCREEN GROUP LIMITED | RIGHTS ISSUE OFFER DOCUMENT l 12
BUSINESS OVERVIEW
device in two top hospitals in Southern
Vietnam, with a further four evaluations
by Ministry of Health underway. A roll-
out of TruScreen into community medical
centres is scheduled in 2H CY2023.
9A TruScreen seminar hosted by Tu Du
Hospital, the most influential gynaecologic
hospital in South Vietnam, was held on 13
December 2022 and received substantial
interest and positive feedback on the
performance of TruScreen. The seminar
was attended by more than 100 doctors.
9TruScreen and its distributor, Gorton Health
Services participated in a charity project
in the Central Highlands. which screened
1,000 local women free of charge. This
initiative received strong support and
acclaim from the local government and
opened the door for TruScreen to enter a
region with population of nearly 6 million.
9In Saudi Arabia, Dr Sulaiman Al Habib
Medical Group (SHMG) the largest private
clinic network has completed a clinical
evaluation and the results on 508 women
are pending.
9TruScreen successfully completed delivery
of its first global virtual medical symposium
to key opinion leaders from 7 countries, on
the place of innovative technologies in
cervical cancer screening. The speakers
at the medical symposium were Associate
Professor Michael Campion, Head of the
Pre-Invasive Clinic at the Gynaecological
Cancer Centre of the Royal Hospital
for Women in Sydney, Professor Hextan
Ngan, Chair Professor in Obstetrics and
Gynaecology, Department of Obstetrics
and Gynaecology, University of Hong
Kong, Associate Professor Fei Chen of
Peking Union Medical College Hospital in
China, Dr Bernard Madzima, the CEO of
the National AIDS Council in Zimbabwe
and Dr Majed Alhudhud, the Director of
Gynaecology Oncology Services at the
Aryan Hospital Medical Group, Riyadh,
Saudi Arabia. The symposium was
attended by 132 doctors from 7 countries.
More specific details of milestones achieved
and activities in 2022 are presented below:
9TruScreen has established a
manufacturing facility in China and is now
registered as a domestic medical device
with its Made in China mark.
9TruScreen’s China distributor Beijing
Siweixiangtai Technology Company
Ltd (SWXT) relaunched distribution of
TruScreen cervical cancer screening
device to Xinjiang Uygur Autonomous
Region. The Xinjiang UAR has a population
of 26 million spread over an area of
1.7 million sq km and the Xinjiang UAR
government is providing special funding
for cancer screening programmes.
9TruScreen has recently been added to the
cervical cancer screening protocol in the
largest medical check-up centre in China.
The centre within the PLA 301 General
Hospital, approved the use of TruScreen in
its cervical cancer screening services. The
health check-up project aims to screen
10,000 women across 10 centres in 3-6
months.
9Completion of a 3 year COGA (Chinese
Obstetricians & Gynaecologists
Association) trial where 15,661 women were
screened across 64 hospitals. Professor
Fei Chan presented her report on the
excellent results at the American Society
of Colposcopy ad Cervical Pathology
Annual Congress in San Diego, California.
9A TruScreen-based cervical cancer
screening centre was opened in Ciudad
de Mexico (Mexico City), operated by
Mexpharm Medical Clinical.
9The National Aids Council’s (NAC) of
Zimbabwe TruScreen Masvingo pilot
project continues to make good progress.
In December 2022, over 5,000 women
have been screened using TruScreen
device.
9In addition to the Hanoi Gynaecological
Hospital, TruScreen recently received
approvals for clinical use of its screening

TRUSCREEN GROUP LIMITED | RIGHTS ISSUE OFFER DOCUMENT l 13
BUSINESS OVERVIEW
Further Resources
Scientific publications 2020-2022:
• Fei Chen et al., COGA Presentation#001051:
Evaluation of an AI Powered Optoelectronic
Technology in Cervical Cancer Screening,
American Society of Colposcopy ad
Cervical Pathology Annual Congress in San
Diego, California, 2022
• Jessica N Vet et al., A Performance
Evaluation of an Optoelectronic Cervical
Screening Device in Comparison to
Cytology and HPV DNA Testing, Eur. J.
Gynaecol. Oncol. 2022; 43(2): 213–218
http://doi.org/10.31083/j.ejgo4302027
• Y. Wei, W. Wang, M. Cheng et al., Clinical
evaluation of a real-time optoelectronic
device in cervical cancer screening,
European Journal of Obstetrics &
Gynecology and Reproductive Biology,
https://doi.org/10.1016/j.ejogrb.2021.09.027
• Comparison of the detection rate of
cervical lesion with TruScreen, LBC test
and HPV test: A Real-world study based
on population screening of cervical cancer
in rural areas of China, Yu Ma, Jiangli Di ,
Hui Bi, et al., https://doi.org/10.1371/journal.
pone.0233986
9TruScreen held dedicated booths at two
national Congresses in 2022: in Mexico
and Poland.
9TruScreen was recognised and awarded
the Quality and Innovation Mark by the
Polish Medical University of Lodz, the fourth
largest city in Poland. Polish University of
Technology, Lodz
9TruScreen is currently transitioning its
regulatory processes to comply with the
new Medical Device Regulation (MDR)
which is mandatory in May 2024.

TRUSCREEN GROUP LIMITED | RIGHTS ISSUE OFFER DOCUMENT l 14
Terms of the Offer
Payment for the New Shares (together with any
additional New Shares applied for under the
Oversubscription Bookbuild Facility) must be
made in full on application with a completed
Entitlement and Acceptance Form delivered to
the Share Registrar, or by completing an online
application at https://Truscreen.rightsoffer.
co.nz, in accordance with the instructions set
out in the Entitlement and Acceptance Form.
If you are an NZX Shareholder, you must elect
to apply using New Zealand dollars at the NZ$
price. If you are an ASX Shareholder, you must
elect to apply using Australian dollars at the
A$ price.
TruScreen may (at its discretion) accept late
applications and Application Monies, but has
no obligation to do so. TruScreen may accept
or reject (at its discretion) any Entitlement and
Acceptance Form which it considers is not
completed correctly, and may correct any
errors or omissions on any Entitlement and
Acceptance Form.
If an Eligible Shareholder does not renounce
their Rights and does not apply for any New
Shares and pay the associated Application
Monies by the Closing Date (5.00pm (NZDT) on
15 March 2023) , their Rights will lapse.
Application Monies received will be held in a
trust account with the Share Registrar until
the corresponding New Shares are allotted or
the Application Monies are refunded. Interest
earned on the Application Monies will be
for the benefit, and remain the property, of
TruScreen and will be retained by TruScreen
whether or not the issue and allotment of New
Shares takes place.
Any refunds of Application Monies will be made
within five Business Days of allotment, or, if a
decision is made not to proceed with the Offer,
within five Business Days of the date of that
decision.
Once submitted, and subject to all applicable
law, an Application is irrevocable and cannot
be withdrawn.
The Offer
The Offer is an offer of New Shares in TruScreen
to Eligible Shareholders under a pro-rata
renounceable rights issue, followed by an
Oversubscription Bookbuild Facility. Under
the Offer, Eligible Shareholders are entitled to
subscribe for one (1) New Share for every five (5)
Existing Shares held on the Record Date. Any
fractional Entitlements will be rounded down
to the nearest whole number.
The New Shares will be of the same class as,
and rank equally with, the Existing Shares
which are quoted on the NZX Main Board and
the ASX. It is a term of the Offer that TruScreen
will take any necessary steps to ensure that
the New Shares are quoted immediately after
the issue.
The Rights will not be quoted on the NZX Main
Board or the ASX. Eligible Shareholders may:
• take up all or some of their Rights; and/or
• sell all or some of their Rights privately.
Eligible Shareholders who take up their Rights
in full may also apply for additional New Shares
under the Oversubscription Bookbuild Facility.
The maximum number of New Shares being
offered under the Offer is 72,573,250 New
Shares. TruScreen may at its discretion elect
to issue additional Shares under the 15%
placement rule of the Listing Rules if there is
demand for New Shares in excess of the size
of this Offer. In the event that this occurred,
the issue price for those Shares issued outside
the parameters of this Offer would be the
same as the Oversubscription Price referred
to in the paragraph below under the heading
“Oversubscription Bookbuild Facility”.
Issue Price and Application Monies
The Issue Price under the Offer is NZ$0.03
(A$0.029) per New Share. The A$ price has
been set by TruScreen taking into account
the A$:NZ$ exchange rate published by the
Reserve Bank of New Zealand on its website at
5pm on 16 February 2023.

TRUSCREEN GROUP LIMITED | RIGHTS ISSUE OFFER DOCUMENT l 15
TERMS OF THE OFFER
Please note that if the buyer of your Rights is an
Ineligible Shareholder or a person that would be
an Ineligible Shareholder were they a registered
holder of Shares, that buyer will not be able to
take up the Rights they have purchased.
Eligible Shareholders who take up all of their
Rights are entitled to apply for additional
New Shares pursuant to the Oversubscription
Bookbuild Facility. This process may also involve
institutional and other investors. Investors who
acquire Rights privately and are not Eligible
Shareholders on the Record Date are not
entitled to make an Application for additional
New Shares under the Oversubscription
Bookbuild Facility but may be able to
participate through an NZX Firm or other market
participant who has been invited to participate
in the Oversubscription Bookbuild Facility.
Oversubscription Bookbuild Facility
Any New Shares in respect of which Rights
are not taken up will form the Shortfall
and will be available to Applicants under
the Oversubscription Bookbuild Facility.
Accordingly, Applicants may apply for an
additional New Shares in excess of the Rights
they hold, subject to the resulting availability.
If Oversubscription Bookbuild Facility
applications exceed the amount of the
Shortfall then such applications will be satisfied
as follows:
• firstly, preference to participate in the
Oversubscription Bookbuild Facility
will be given to existing Shareholders
(registered as holders of Existing Shares
as at the Record Date) ahead of those
parties wishing to participate in the
Oversubscription Bookbuild Facility, who
were not Shareholders as at the Record
Date; and
• secondly, on a pro-rata basis (calculated
based on the proportion of Existing
Shares held by each Applicant to the
Oversubscription Bookbuild Facility
as at the Record Date) up to the total
number of New Shares comprising the
Oversubscription Bookbuild Facility.
Eligibility
The Offer is only open to Eligible Shareholders
or persons that TruScreen is satisfied can
otherwise participate in the Offer in compliance
with all applicable laws.
TruScreen considers that the legal
requirements of jurisdictions other than New
Zealand and Australia are such that it would
be unduly onerous for TruScreen to make the
Offer in those jurisdictions. This decision was
made having regard to the small number of
Shareholders in such overseas jurisdictions, the
financial resources of TruScreen and the costs
of complying with overseas legal requirements.
This Offer Document is intended for use only
in connection with the Offer to any person
recorded in TruScreen’s share register as a
Shareholder on the Record Date (5.00pm
(NZDT) 27 February 2023):
• whose address is shown in TruScreen’s
share register as being in New Zealand; or
• whose address is shown in TruScreen’s
share register as being in Australia.
This Offer Document is not to be sent or given to
any person outside New Zealand or Australia in
circumstances in which the Offer or distribution
of this Offer Document would be unlawful.
Opening and Closing Dates
The Offer will open for receipt of acceptances
from 28 February 2023 (Opening Date). The last
day for receipt of the completed Acceptance
and Entitlement Form with payment is 5.00pm
(NZDT) on 15 March 2023 (Closing Date),
subject to TruScreen varying those dates in
accordance with the Listing Rules.
No Rights Trading
The Rights will not be quoted on the NZX Main
Board or the ASX, and accordingly there will be
no established market for Rights. If you wish to
sell your Rights privately to a buyer you identify,
you should contact the Registrar, Link Market
Services (see Directory), to request a Security
Renunciation Form.

TRUSCREEN GROUP LIMITED | RIGHTS ISSUE OFFER DOCUMENT l 16
TERMS OF THE OFFER
From the proceeds received from the issue of the
New Shares pursuant to the Oversubscription
Bookbuild Facility, the Issue Price of NZ$0.03
(A$0.029) shall be payable to TruScreen. Any
premium received above that Issue Price, ie
the difference between the Issue Price and the
Oversubscription Price (net of any amounts
required to be withheld), will be ultimately paid
on a pro-rata basis to the holders of those
Rights that were not ultimately exercised in
proportion to their holdings of unexercised
Rights.
Allotment of New Shares
New Shares issued pursuant to the exercise
of Entitlements are expected to be allotted
and issued by 22 March 2023 (Allotment
Date). Transaction statements confirming the
allotment of your New Shares will be issued and
mailed in accordance with the Listing Rules.
Quotation of New Shares
The New Shares have been accepted for
quotation by NZX and will be quoted upon
completion of allotment procedures. The NZX
Main Board is a licensed market operated
by NZX, which is a licensed market operator
regulated under the FMCA. An application will
also be made by TruScreen for the New Shares
to be issued under the Offer to be quoted on
ASX.
However, neither NZX nor ASX accepts no
responsibility for any statement in this Offer
Document. The fact that ASX may approve the
New Shares for quotation is not to be taken
in any way as an indication of the merits of
TruScreen.
TruScreen reserves the right to determine
who may participate in the Oversubscription
Bookbuild and may decline or scale applications
for New Shares by any Eligible Shareholder, or
third-party investor as it sees fit.
Eligible Shareholders who wish to participate
in the Oversubscription Bookbuild Facility may
do so, provided they have fully taken up all of
their Rights by:
• in the case of NZX Shareholders, specifying
the NZ$ amount of New Shares they
wish to apply for on the Entitlement and
Acceptance Form where provided; or
• in the case of ASX Shareholders, specifying
the A$ amount of New Shares they wish
to apply for on the Entitlement and
Acceptance Form where provided,
and must pay that NZ$ or A$ amount of
additional New Shares being applied for under
the Oversubscription Bookbuild Facility in
addition to their Application Monies for their
Rights.
In the case of third-party investors who
have been invited to participate in the
Oversubscription Bookbuild Facility, those
parties shall bid for the New Shares attributed
to the Shortfall. The minimum bid price shall
not be less than the Issue Price. There is no
maximum bid price.
The final price for the New Shares to be issued
pursuant to the Oversubscription Bookbuild
Facility (Oversubscription Price) will be
determined by TruScreen and its advisors by
reference to the Oversubscription Bookbuild
Facility having regard to the bids for New
Shares received (and their corresponding
number of New Shares bid for at those levels)
from those NZX Firms and institutions invited to
bid into the Oversubscription Bookbuild Facility.
In no event will the issue price for the New
Shares under the Oversubscription Bookbuild
Facility be less than the Issue Price, however
it may be equal to, or greater than the Issue
Price. There is however no guarantee that the
final Oversubscription Price will exceed the
Issue Price.

TRUSCREEN GROUP LIMITED | RIGHTS ISSUE OFFER DOCUMENT l 17
TERMS OF THE OFFER
d. where the Custodian holds Shares on
behalf of a Participating Beneficiary
indirectly, through one or more Downstream
Custodians, the name and address of
each Downstream Custodian.
Custodians may not distribute this Offer
Document to any person in any country outside
New Zealand and Australia.
Terms and Ranking of New Shares
New Shares allotted and issued will be fully
paid and will be the same class as, and rank
equally in all respects with, Existing Shares on
issue that are quoted on the Main Board on the
Allotment Date. They will give the holder the
right to one vote on a resolution at a meeting
of Shareholders (subject to any restrictions in
TruScreen’s constitution or the Listing Rules),
the right to dividends authorised by the Board
and the right to a proportionate share in any
distribution of surplus assets of TruScreen on
any liquidation. Applicants for New Shares will
be bound by TruScreen’s constitution and the
terms of the Offer set out in this Offer Document.
No Minimum Amount to be Raised
There is no minimum amount that must be
raised for the Offer to proceed.
Custodians
Under the Offer, a custodian (Custodian) is any
Eligible Shareholder having a registered address
in New Zealand, that:
a. is a trustee corporation or a nominee
company and holds Shares in TruScreen
by reason only of acting for another
person in the ordinary course of business
of that trustee corporation or nominee
company; or
b. holds Shares in TruScreen by reason only of
being a bare trustee of a trust to which the
Shares are subject.
Custodians must confirm to TruScreen that they
are holding Existing Shares as a Custodian for
one or more beneficial owners (Participating
Beneficiary) and certify the matters described
below by email, together with the Custodian’s
Application Form.
a. the number of Participating Beneficiaries
and their names and addresses;
b. in respect of each of the Participating
Beneficiaries;
(i) the number of Existing Shares that the
Custodian holds on behalf of each
Participating Beneficiary and the
number and dollar amount of Rights;
and
(ii) the dollar amount of any additional
New Shares in the Oversubscription
Bookbuild Facility (if eligible),
that each Participating Beneficiary has
instructed the Custodian, either directly
or indirectly through a Downstream
Custodian, to apply for on their behalf;
c. that a copy of this document was given to
each Participating Beneficiary; and

TRUSCREEN GROUP LIMITED | RIGHTS ISSUE OFFER DOCUMENT l 18
TERMS OF THE OFFER
Brokerage
No brokerage is payable by Eligible
Shareholders who accept their Entitlement.
Governing Law
This Offer Document, the Offer and any contract
resulting from it are governed by the laws of
New Zealand, and each Applicant submits to
the exclusive jurisdiction of the courts of New
Zealand.
Amendments to the Offer and Waiver of
Compliance
Notwithstanding any other term or condition of
the Offer, TruScreen may at its discretion:
• make non-material modifications to the
Offer on such terms and conditions as
it sees fit (in which event applications for
Shares under the Offer will remain binding
on the Applicant notwithstanding such
modification and irrespective of whether an
application was received by the Registrar
before or after such modification is made);
and/or
• suspend or terminate the Offer at any
time prior to the issue of the New Shares
under the Offer (including by reviewing
the timetable for the Offer). If the Offer is
terminated, application monies will be
refunded to Applicants without interest
within 5 Business Days of termination.
TruScreen reserves the right to waive compliance
with any provision of these terms and conditions.
TruScreen will notify NZX and ASX of any waiver,
amendment, variation, suspension, withdrawal
or termination of the Offer.

TRUSCREEN GROUP LIMITED | RIGHTS ISSUE OFFER DOCUMENT l 19
Glossary
Allotment Datemeans the date for allotment of New Shares under the Offer,
expected to be on or about 22 March 2023.
Applicantmeans an investor whose application for New Shares has been
received by the Registrar.
Applicationmeans an application to subscribe for New Shares under this
Offer Document.
Application Moniesmeans monies received from Applicants in respect of their
Applications.
ASICmeans the Australian Securities and Investments Commission.
ASXmeans ASX Limited or the Australian Securities Exchange
operated by ASX Limited, as the context may require.
ASX Shareholdermeans an Eligible Shareholder whose Existing Shares are held
on TruScreen’s ASX branch register on the Record Date.
Boardmeans the board of directors of TruScreen.
Business Dayhas the meaning given to that term in the Listing Rules.
Closing Datemeans 5:00pm (NZDT) on 15 March 2023.
Eligible Shareholdermeans a Shareholder who as at the Record Date is registered
as a Shareholder, and has a registered address in New
Zealand or Australia.
Entitlementmeans the number of Rights to which Eligible Shareholders are
entitled.
Entitlement and
Acceptance Form
means the personalised entitlement and acceptance form
accompanying this Offer Document for Eligible Shareholders.
Existing Sharemeans a Share on issue on the Record Date.
Ineligible Shareholdersmeans Shareholders other than Eligible Shareholders.
Issue Pricemeans NZ$0.03 (A$0.29) per New Share.
Listing Rulesmeans the NZX Listing Rules.
Main Boardmeans the NZX Main Board.
New Sharemeans an ordinary share in TruScreen offered under the Offer
of the same class as (and ranking equally in all respects with)
Existing Shares at the time of allotment of the New Shares.
TRUSCREEN GROUP LIMITED | RIGHTS ISSUE OFFER DOCUMENT l 19

TRUSCREEN GROUP LIMITED | RIGHTS ISSUE OFFER DOCUMENT l 20
Glossary
NZXmeans NZX Limited.
NZX Firmmeans an entity designated as an NZX Firm under the
Participant Rules of NZX.
NZX Shareholdermeans an Eligible Shareholder whose Existing Shares are held
on TruScreen’s NZX branch register on the Record Date.
Offermeans the offer of New Shares to Eligible Shareholders as at
the Record Date, under the renounceable rights offer set out
in this Offer Document, together with the Oversubscription
Bookbuild Facility.
Offer Documentmeans this document.
Opening Datemeans 28 February 2023.
Oversubscription
Bookbuild Facility
means the facility comprised of the Shortfall and available for
subscription to Applicants on the terms described in this Offer
Document.
Oversubscription Pricemeans the price at which New Shares are to be issued under
the Oversubscription Bookbuild Facility.
Record Datemeans 5:00pm (NZDT) on 27 February 2023 .
Registrar or Share
Registrar
means Link Market Services Limited.
Rightmeans the renounceable right to subscribe for 1 New Share for
every 5 Existing Shares held on the Record Date at the Issue
Price, issued pursuant to the Offer.
Sharemeans one fully paid ordinary share in TruScreen.
Shareholdermeans a registered holder of Shares on issue.
Shortfall means the number of Rights not exercised by Shareholders.
TruScreenmeans TruScreen Group Limited.
TRUSCREEN GROUP LIMITED | RIGHTS ISSUE OFFER DOCUMENT l 20

TRUSCREEN GROUP LIMITED | RIGHTS ISSUE OFFER DOCUMENT l 21
Directory
IssuerTruScreen Group Limited
c/- HLB Mann Judd Limited
Level 6, Equitable House
57 Symonds Street, Grafton
Auckland, 1010
New Zealand
T: +64 9 303 2243
E: hlb@hlb.co.nz
Directors of
Truscreen Group
Limited
Anthony Ho (Chairman)
Dr. Dexter Cheung
Christopher Horn
Juliet Hull
Executive
Management
Dr. Beata Edling (CEO)
Guy Robertson (CFO)
RegistrarLink Market Services Limited
PwC Tower
Level 30/15 Customs Street West
Auckland CBD, 1010
PO Box 91976
Victoria Street West
Auckland 1142
Toll free: 0800 377 388
T: 64 9 375 5998
W: linkmarketservices.co.nz
E: enquiries@linkmarketservices.co.nz
Capital Markets
Advisor
CM Partners Limited
PO Box 105 745
Auckland 1143
www.cmpartners.co.nz
Legal AdvisorsNZ legal advisor:
Sean Joyce – Corporate Counsel
PO Box 42 258, Orakei
Auckland 1745
Australian legal advisor:
Addisons
Level 12, 60 Carrington Street
Sydney NSW 2000
www.addisons.com
TRUSCREEN GROUP LIMITED | RIGHTS ISSUE OFFER DOCUMENT l 21